Welcome to the Arvinas fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

A protein called B cell lymphoma 6 could be key to maintaining healthy muscle mass and potentially could be used to combat ...

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...

New research highlights the potential of the protein BCL6 in preserving muscle mass, especially when used with popular weight loss drugs. The study, by the Salk Institute, suggests therapeutic ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...

The results suggest that pairing GLP-1 medications with a BCL6-boosting drug may help counteract unwanted muscle loss. Similar therapies could also be used to treat other populations prone to muscle ...

Maintaining muscle mass is crucial for health, and researchers have identified the protein BCL6 as vital for this. Studies reveal GLP-1 medications for weight loss can cause muscle loss ...

A new study from the Salk Institute has revealed that a protein called BCL6 is key to maintaining healthy muscle mass. The experiments showed that mice with lower levels of BCL6 had significantly ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at exploring immune-related genes and their expression changes in myocardial ...